Camp4 Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Camp4 Therapeutics (CAMP).

Price Target Range — 8 Quarters

Analyst Consensus — 12 Analysts

1S.Buy

10Buy

1Sell

Consensus RatingOverweight# Analysts12Avg. Consensus PT$10Upside to Avg. PT+148.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 23, 2026	Raymond James	Tiago Fauth	Initiate	Strong Buy	$10
Oct 15, 2026	Needham	Joseph Stringer	Initiate	Buy	$8
Oct 5, 2026	Oppenheimer	Kostas Biliouris	Initiate	Outperform	$15
Sep 29, 2026	Chardan Capital	Keay Nakae	PT Cut	Buy	$7→$6
Aug 14, 2026	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$12→$15
Jun 16, 2026	JP Morgan	Anupam Rama	Upgrade	Neutral→Overweight	$5→$9
Jun 10, 2026	Chardan Capital	Keay Nakae	Initiate	Buy	$7
Apr 14, 2026	Rodman & Renshaw	Seema Sheoran	Initiate	Buy	$7
Apr 2, 2026	Leerink Partners	Mani Foroohar	PT Raise	Outperform	$8→$9
Oct 2, 2025	Cantor Fitzgerald	Steve Seedhouse	Initiate	Overweight	$7
Sep 16, 2025	JP Morgan	Anupam Rama	Downgrade	Overweight→Neutral	—
Sep 15, 2025	Piper Sandler	Edward Tenthoff	PT Cut	Overweight	$18→$12
May 27, 2025	Wedbush	Yun Zhong	Initiate	Outperform	$8
Nov 5, 2024	William Blair	Myles Minter	Initiate	Outperform	—
Nov 5, 2024	Leerink Partners	Mani Foroohar	Initiate	Outperform	$17
Nov 5, 2024	JP Morgan	Eric Joseph	Initiate	Overweight	$23
Nov 5, 2024	Piper Sandler	Edward Tenthoff	Initiate	Overweight	$18
Jan 11, 2024	Goldman Sachs	Jerry Revich	PT Cut	Sell	$8→$7

Analyst Ratings News

PRO
Raymond James Initiates Coverage On Camp4 Therapeutics with Strong Buy Rating, Announces Price Target of $10

Raymond James analyst Tiago Fauth initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Strong Buy rating and announces Price Target of $10.

Benzinga Newsdesk

PRO
Needham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8

Needham analyst Joseph Stringer initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $8.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6

Chardan Capital analyst Keay Nakae maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Buy and lowers the price target from $6.5 to $6.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15

Piper Sandler analyst Edward Tenthoff reiterates Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight and raises the price target from $12 to $15.

Benzinga Newsdesk

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics, PennyMac Financial, Dave & Buster's, Neumora Therapeutics, Extra Space Storage, & W. P. Carey. See full list here.

Avi Kapoor

This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Top analysts upgraded XOM, CAMP, EXR, WPC, and KRC stocks, with price targets ranging from $44 to $154. See other analysts' views on these stocks.

Avi Kapoor

Camp4 Therapeutics Corp

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Camp4 Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Raymond James Initiates Coverage On Camp4 Therapeutics with Strong Buy Rating, Announces Price Target of $10

PRO
Needham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8

PRO
Chardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6

PRO
Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

People Also Watch

People Also Watch

Camp4 Therapeutics Corp

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Camp4 Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORaymond James Initiates Coverage On Camp4 Therapeutics with Strong Buy Rating, Announces Price Target of $10

PRONeedham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8

PROChardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6

PROPiper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

People Also Watch

People Also Watch

PRO
Raymond James Initiates Coverage On Camp4 Therapeutics with Strong Buy Rating, Announces Price Target of $10

PRO
Needham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8

PRO
Chardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6

PRO
Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15